Sugi Predict

Sugi Predict / Compounds / SCHEMBL2500536

SCHEMBL2500536

SCHEMBL2500536

O=C1Nc2cnccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 6/20 0.52
▸ MAOB P27338 6/20 0.52
▸ PDE3B Q13370 2/20 0.51
▸ PDE3A Q14432 2/20 0.51
▸ CES1 P23141 5/20 0.46
▸ TGM2 P21980 6/20 0.44
▸ CDC25B P30305 1/20 0.44
▸ CDC7 O00311 2/20 0.41
▸ ROCK2 O75116 2/20 0.41
▸ MAP4K4 O95819 2/20 0.41
▸ PRKACA P17612 2/20 0.41
▸ CDK2 P24941 2/20 0.41
▸ GSK3B P49841 2/20 0.41
▸ HIPK2 Q9H2X6 2/20 0.41
▸ CLK4 Q9HAZ1 2/20 0.41
▸ IRAK4 Q9NWZ3 2/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41
▸ CASP3 P42574 1/20 0.39
▸ CASP2 P42575 1/20 0.39
▸ CASP7 P55210 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29974124 1.00 MAOA (0.52) MAOAMAOBPDE3BPDE3ACES1
SCHEMBL562478 0.83 PDE3B (0.56) MAOAMAOBPDE3BPDE3ACES1
SCHEMBL2344184 0.73 SMN1; SMN2 (0.61) TGM2GSK3B
SCHEMBL2344188 0.73 SMN1; SMN2 (0.61) TGM2GSK3B
SCHEMBL6480632 0.72 SMN1; SMN2 (0.50) MAOAMAOBPDE3BPDE3ACDC7
SCHEMBL6480637 0.72 SMN1; SMN2 (0.50) MAOAMAOBPDE3BPDE3ACDC7
Isatin SCHEMBL4092377 0.71 MAOA (0.95) MAOAMAOBCES1TGM2GSK3B
SCHEMBL31318 0.71 GSK3B (0.50) MAOAMAOBPDE3BPDE3ACDC25B
Isatin SCHEMBL25309042 0.71 MAOA (0.74) MAOAMAOBPDE3BPDE3ATGM2
SCHEMBL30824145 0.69 MAOA (0.39) MAOAMAOBPDE3BPDE3ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143182-B1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2024-12-11 — — EP disclosed
EP-4244224-A1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2023-09-20 — — EP disclosed
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 — — US disclosed
CN-115485271-A Novel compounds as inhibitors of poly (ADP-ribose) polymerase (PARP) 理森制药股份公司 2022-12-16 — — CN disclosed
CN-113461679-B Synthesis of benzazepine isatin compound 石药集团中奇制药技术（石家庄）有限公司 2022-09-30 — — CN disclosed
WO-2022104348-A1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2022-05-19 — — WO disclosed
CN-113461679-A Synthesis of benzazepine isatin compound 石药集团中奇制药技术（石家庄）有限公司 2021-10-01 — — CN disclosed
US-20200131144-A1 AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS PHENEX-FXR GMBH (DE) 2020-04-30 — — US disclosed
WO-2019016269-A1 AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS PHENEX-FXR GMBH (DE) 2019-01-24 — — WO disclosed
US-9481670-B2 Triazine compounds SPHAERA PHARMA PTE. LTD. (SG) 2016-11-01 — — US disclosed
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 — — US disclosed
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 — — US disclosed
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 — — US disclosed
EP-1343499-A4 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2004-05-06 — — EP disclosed
US-20040067997-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents YU KUO-LONG (US) 2004-04-08 — — US disclosed
EP-1343499-A2 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-09-17 — — EP disclosed
WO-2002062290-A2 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-15 — — WO disclosed
US-20020099208-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2002-07-25 — — US disclosed
US-5441955-A Tuberculosis PATHOGENESIS CORPORATION (US) 1995-08-15 — — US disclosed
WO-1995013807-A1 INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF PATHOGENESIS CORPORATION (US) 1995-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099208-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents MAVS, ZC3HAV1, EIF2AK2 MAOA 2948/4885MAOB 2019/4885PDE3B 1992/4885
US-20040067997-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents MAVS, ZC3HAV1, EIF2AK2 MAOA 2948/4885MAOB 2019/4885PDE3B 1992/4885
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 MAOA 1200/4885MAOB 1128/4885PDE3B 3195/4885
US-20200131144-A1 AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS NR1H2, NR1H3, NR1H4 MAOA 3015/4885MAOB 2585/4885PDE3B 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.